Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer

Bilal A Siddiqui1, Sumit K Subudhi1, Padmanee Sharma2

  • 1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.